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Abstract Non-alcoholic fatty liver disease (NAFLD) is
characterized by hepatic lipid accumulation in the absence
of excess alcohol intake. NAFLD is the most common
chronic liver disease, and ongoing research efforts are
focused on understanding the underlying pathobiology of
hepatic steatosis with the anticipation that these efforts will
identify novel therapeutic targets. Under physiological
conditions, the low steady-state triglyceride concentrations
in the liver are attributable to a precise balance between
acquisition by uptake of non-esteriﬁed fatty acids from the
plasma and by de novo lipogenesis, versus triglyceride
disposal by fatty acid oxidation and by the secretion of
triglyceride-rich lipoproteins. In NAFLD patients, insulin
resistance leads to hepatic steatosis by multiple mecha-
nisms. Greater uptake rates of plasma non-esteriﬁed fatty
acids are attributable to increased release from an expanded
mass of adipose tissue as a consequence of diminished
insulin responsiveness. Hyperinsulinemia promotes the
transcriptional upregulation of genes that promote de novo
lipogenesis in the liver. Increased hepatic lipid accumula-
tion is not offset by fatty acid oxidation or by increased
secretion rates of triglyceride-rich lipoproteins. This review
discusses the molecular mechanisms by which hepatic tri-
glyceride homeostasis is achieved under normal conditions,
as well as the metabolic alterations that occur in the setting
of insulin resistance and contribute to the pathogenesis of
NAFLD.
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Introduction
Non-alcoholic fatty liver disease (NAFLD) is a major
public health issue due to its high prevalence worldwide
and potentially serious sequelae. NAFLD is an overarching
term for liver histopathology that encompasses a spectrum
from simple steatosis to non-alcoholic steatohepatitis
(NASH). Whereas simple steatosis is characterized by a
relatively favorable clinical course, NASH much more
frequently progresses to cirrhosis and hepatocellular car-
cinoma [1, 2]. NAFLD is a hepatic manifestation of met-
abolic syndrome and a risk factor for type 2 diabetes
mellitus, dyslipidemia and hypertension [3]. Estimates of
the prevalence of NAFLD range widely from 11 to 46 %
[4, 5]. Apart from weight loss, there are currently no
effective therapies for NAFLD.
Because the liver does not serve as a storage depot for
fat, the steady state concentration of hepatic triglycerides is
low under physiological conditions. Nevertheless, there is
considerable trafﬁcking of both triglycerides and fatty
acids into and out of the liver in response to feeding and
fasting. Dietary fatty acids are absorbed from the small
intestine, assembled into triglycerides and incorporated
into chylomicrons. These are secreted into lymphatics and
enter the plasma as triglyceride-rich chylomicrons, where
they deliver in excess of 70 % of their fatty acids mainly to
adipose tissue, with the remaining being taken up by the
liver [6, 7]. In the setting of excess carbohydrates, fatty
acids are also synthesized de novo within the liver [1].
These fatty acids may be converted into other lipid species,
such as glycerolipids, glycerophospholipids and sterols,
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DOI 10.1007/s00535-013-0758-5which can be packaged into very low density lipoprotein
(VLDL) particles and secreted from the liver into the
plasma. Under fasting conditions, fatty acids are released
from adipose tissue and return to the liver, where they are
assembled into triglycerides and packaged to form VLDL
particles that are secreted into the plasma. Fatty acids may
also be oxidized in situ by mitochondria within the liver.
The hallmark of NAFLD is triglyceride accumulation in
the cytoplasm of hepatocytes. This arises from an imbal-
ance between lipid acquisition (i.e., fatty acid uptake and
de novo lipogenesis) and removal (i.e., mitochondrial fatty
acid oxidation and export as a component of VLDL par-
ticles). Here we review the molecular mechanisms that
underlie physiological processing of fatty acids and tri-
glycerides by the liver together with the pathophysiological
changes that contribute to NAFLD, which are illustrated in
Fig. 1.
Fatty acid uptake
Fatty acid uptake into the liver contributes to the steady
balance of hepatic triglycerides in the liver, as well as the
pathogenesis of NAFLD. The rate of fatty acid uptake from
plasma into cells depends on the fatty acid concentration in
plasma and the hepatocellular capacity for fatty acid uptake
[8]. Because non-esteriﬁed fatty acids are hydrophobic,
they are largely bound to albumin in plasma. The process
of cellular uptake across the plasma membrane is protein-
mediated and requires the dissociation of non-esteriﬁed
fatty acids from albumin [9]. The cellular capacity for fatty
acid uptake depends on the number and activity of trans-
porter proteins on the sinusoidal plasma membrane of the
hepatocyte.
The identiﬁcation and characterization of plasma
membrane transporters has remained an area of active
Fig. 1 Mechanisms of hepatocellular lipid metabolism and their
dysregulation in non-alcoholic fatty liver disease (NAFLD). Fatty
acid uptake: fatty acid transport protein (FATP) 2, FATP5 and CD36
mediate transport of non-esteriﬁed fatty acids (NEFA) across the
plasma membrane. Once taken up into cytosol, fatty acids are
activated to form acyl-CoAs by the activity of FATPs or fatty acyl-
CoA synthetases (ACSs). De novo lipogenesis: palmitic acid is newly
synthesized from glucose. Acetyl-CoA carboxylase (ACC) and fatty
acid synthase (FAS) catalyze the rate-limiting and ﬁnal steps,
respectively. After ACS-mediated activation, palmitoyl-CoA is
elongated by long chain fatty acid elongase 6 (ELOVL6) and
desaturated by stearoyl-CoA desaturase 1 (SCD1). Acyl-CoAs are
esteriﬁed by glycerol-3-phosphate (G-3-P) acyltransferase (GPAT) to
form lysophosphatidic acid (LPA) and by 1-acylglycerol-3-phosphate
acyltransferase (AGPAT) to form phosphatidic acid (PA). PA is
dephosphorylated by lipin 1 to form diacylglycerol (DAG), which is
esteriﬁed to another acyl-CoA molecule to form triglyceride (TG) by
acyl-CoA:diacylglycerol acyltransferase (DGAT). Fatty acid oxida-
tion: acyl-CoAs are transported into mitochondria across the outer
mitochondrial membrane (OMM) and inner mitochondrial membrane
(IMM) by the activities of carnitine palmitoyl transferase (CPT) 1,
CPT2 and carnitine acylcarnitine translocase (CACT). Within mito-
chondria, acyl-CoAs are oxidized to form acetyl-CoA. Very low
density lipoprotein (VLDL) synthesis: TGs are packaged together
with apoB 100 into VLDL in the endoplasmic reticulum (ER) by the
activity of microsomal triglyceride transfer protein (MTP) and
secreted into space of Disse. Pink arrows denote the increases and
decreases that occur in NAFLD and are described in the text. In
NAFLD patients, enhanced acquisition of fatty acids through uptake
and rates of de novo lipogenesis are not compensated by possible
increases in rates of fatty acid oxidation or higher production rates of
VLDL particles
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123discovery. Fatty acid transport proteins (FATPs) and CD36
(also known as fatty acid translocase, FAT) are key con-
tributors to the transmembrane process. Six FATP isoforms
have been identiﬁed in mammalian cells [9, 10]. Of these
isoforms, FATP2 is expressed in liver and kidney whereas
FATP5 is a liver-speciﬁc isoform. In mouse hepatocytes,
adenovirus-mediated knockdown of FATP2 or genetic
deletion of FATP5 signiﬁcantly decreases the rates of fatty
acid uptake [11, 12]. CD36 is expressed in a variety of
tissues and cell types, muscle and adipose tissue, as well as
platelets and macrophages, but its expression level is low
in hepatocytes [13]. Mice lacking CD36 exhibit reduced
muscle triglyceride contents but also hepatic steatosis [14],
supporting the contention that protein-mediated fatty acid
uptake to hepatocytes is mainly attributable to FATPs, at
least under physiological conditions.
After the entry into cells, fatty acids are rapidly activated
by conversion to fatty acyl-CoAs. However, the molecular
details of this process remain incompletely understood. One
possibility is that FATPs themselves possess fatty acyl-CoA
synthetase activity. Puriﬁed FATP1 exhibits both long
chain and very long chain fatty acyl-CoA synthetase
activity [15]. Alternatively, FATPs may interact with long
chain acyl-CoA synthetases (ACSLs), which in turn gen-
erate the fatty acyl-CoAs. In this connection, FATP1 and
ACSL1 were co-immunoprecipitated from 3T3–L1 adipo-
cytes, suggesting that they are interacting proteins [16]. In
mammals, ﬁve ACSLs have been identiﬁed (ACSL1 and
3–6) [17, 18]. In excess of 50 % of the acyl-CoA synthetase
activity in the liver is attributable to ACSL1, which is
abundant in endoplasmic reticulum (ER) and mitochondria
[19]. ACSL5 is also enriched in liver and is mainly local-
ized to mitochondria [20]. Although gain-of-function
experiments have demonstrated that ACSL1 and ACSL5
enhance fatty acid uptake in selected cell lines [21, 22], they
have no effect on fatty acid uptake rate in hepatocytes,
where they appear to channel fatty acids from fatty acid
oxidation to lipid synthesis [20]. This is presumably
because subcellular distribution of these enzymes differs
among cell types. Although it appears unlikely that hepatic
ACSLs are coupled with fatty acid uptake, it remains
uncertain whether hepatic FATPs are solely responsible for
acyl-CoA formation during fatty acid uptake.
Indicative of the importance of fatty acid uptake in
NAFLD pathogenesis, Donnelly et al. [7] have demon-
strated that approximately 60 % of hepatic triglycerides in
human subjects are derived from non-esteriﬁed fatty acids
in the plasma. This is in line with the observation that
plasma non-esteriﬁed fatty acid concentrations are elevated
in NAFLD subjects, an effect that is attributable to
increased fatty acid release from adipose tissue [23, 24].
NAFLD is strongly associated with obesity, and increased
fat mass contributes directly to greater fatty acid release
from adipose tissue [25]. Peripheral insulin resistance in
NAFLD patients also contributes to increased rates of fatty
acid release from adipose tissue [26]. Elevated hepatic
expression levels of CD36 have been observed in NAFLD
and appear to mediate enhanced uptake of non-esteriﬁed
fatty acids [27, 28]. A potential pathogenic role is sup-
ported by the observation that hepatic overexpression of
CD36 in mice increases liver triglyceride contents [29].
Collectively, these ﬁndings support a pathogenic role for
fatty acid uptake in NAFLD.
Recent studies have also suggested that hepatic uptake
of fatty acids via FATPs can be a novel therapeutic strategy
for NAFLD. Adenovirus-mediated knockdown of FATP2
or FATP5 reduced hepatic triglyceride accumulation in
mice fed a high fat diet [12, 30]. Moreover, both deoxy-
cholic and ursodeoxycholic acid have shown promise as
inhibitors of FATP5-mediated fatty acid uptake, suggesting
that bile acid treatment may improve hepatic steatosis, at
least in high fat fed mice [31].
Triglyceride synthesis
The non-esteriﬁed fatty acids that are incorporated into
triglycerides within liver may be derived from the plasma or
be newly synthesized from glucose (so-called ‘‘de novo
lipogenesis’’). De novo lipogenesis plays a substantial role
in the pathogenesis of NAFLD,accounting for 26 % hepatic
triglycerides in human subjects [7]. Here we describe the
mechanisms of hepatic triglyceride accumulation through
de novo lipogenesis under physiological conditions fol-
lowed by their aberrant regulation in NAFLD.
For de novo lipogenesis, glucose is converted to acetyl-
CoA through glycolysis and the oxidation of pyruvate.
Acetyl-CoA is then converted to malonyl-CoA by acetyl-
CoA carboxylase (ACC). Fatty acid synthase (FAS) cata-
lyzes the formation of palmitic acid from malonyl-CoA and
acetyl-CoA. Palmitic acid is then elongated and desaturated
by long chain fatty acid elongase 6 (ELOVL6) and stearoyl-
CoAdesaturase1(SCD1)togeneratemonounsaturatedfatty
acids, which are the major fatty acid constituents of tri-
glycerides. Glycerol-3-phosphate acyltransferase (GPAT)
then catalyzes the esteriﬁcation of glycerol-3-phosphate
from glycolysis with the newly synthesized fatty acid to
generatelysophosphatidicacids.Lysophosphatidicacidsare
substrates for 1-acylglycerol-3-phosphate acyltransferase
(AGPAT) to catalyze the formation of phosphatidic acids.
Phosphatidic acids are then processed to diacylglycerols by
lipin 1 [32], followed by the formation of triglycerides
through acyl-CoA:diacylglycerol acyltransferase (DGAT).
Lipogenesis is controlled primarily at the transcriptional
level [32, 33]. Postprandially, plasma glucose and insulin
concentrations rise, and both are required for full activation
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123of lipogenesis [33]. Glucose and insulin promote lipogen-
esis by activation of carbohydrate response element bind-
ing protein (ChREBP) and sterol regulatory element
binding protein 1c (SREBP1c), respectively. These are
master transcription factors, which in turn promote tran-
scription of lipogenic genes.
SREBP1c is a transcription factor that promotes the
expression of lipogenic genes, including FAS, ACC, SCD1
and lipin 1 [32, 34]. Insulin promotes the transcriptional
upregulation of SREBP1c by an incompletely understood
phosphoinositide 3-kinase (PI3K)-dependent mechanism
that relies upon the participation of liver X receptor (LXR)
[33]. LXR, a nuclear hormone receptor that also plays a
key role in regulating cellular cholesterol homeostasis, is
activated by oxysterol metabolites of cholesterol [35].
Once activated, LXR heterodimerizes with the retinoid X
receptor (RXR) and binds to the LXR response element,
leading to upregulation of target genes involved in cho-
lesterol catabolism and elimination [35]. Of the two iso-
forms of LXR, LXRa is the predominant isoform in liver
[35] and a potent activator of SREBP1c [33, 36].
ChREBP also plays an important role in glucose-medi-
ated lipogenesis within the liver. ChREBP is a glucose-
responsive transcription factor that relocates to the nucleus
in response to increased glucose concentrations. Glucose
promotes dephosphorylation of amino acid residues on
ChREBP, and this results in transport into the nucleus and
binding to the gene promoters [33]. ChREBP stimulates the
expression of lipogenic genes, but also the expression of
liver-type pyruvate kinase, thus providing more substrate
for fatty acid and triglyceride synthesis [1, 37].
The term ‘‘selective insulin resistance’’ has been used to
describe the metabolic events within the liver that appear to
contribute to NAFLD pathogenesis. Muscle and liver
insulin resistance develops in the setting of overnutrition
by mechanisms that are complex, but converge to promote
the accumulation of speciﬁc lipid metabolites (i.e., dia-
cylglycerols and/or ceramides) in liver and skeletal muscle
that impair insulin signaling and promote insulin resistance
[38]. Notwithstanding its failure to suppress hepatic glu-
coneogenesis, insulin continues to promote lipogenesis
within the liver. Mechanisms of this selective insulin
resistance are the subject of active investigation. Within the
insulin signaling pathway, the mammalian target of rapa-
mycin complex 1 (mTORC1) and insulin induced gene 2A
(INSIG2A) are required for stimulation of lipogenesis [39,
40], but apparently not for inhibition of gluconeogenesis
[39], which is regulated by the transcription factor forkhead
box O1 (FoxO1). This divergence in responses could
explain how glucose and lipid metabolism might be sepa-
rately controlled within the same pathway. It has also been
proposed that ER stress in the context of overnutrition
leads to cellular processing and activation of SREBP1c,
which promotes lipogenesis and contributes to the devel-
opment of hepatic steatosis [33].
Fatty acid oxidation
The steady state balance of hepatic triglycerides is also
controlled by the consumption of fatty acids by mito-
chondrial b-oxidation [41], which is critical for production
of both ATP and ketone bodies. Fatty acyl-CoAs, the
activated form of fatty acids, traverse mitochondrial
membranes in a carnitine-dependent manner. The presence
of an acyl-CoA synthetase in the outer mitochondrial
membrane suggests that activation of fatty acids for mito-
chondrial uptake occurs as an initial step in the transport
process. Translocation of fatty acyl-CoAs across the outer
mitochondrial membrane is coupled to their conversion to
acyl-carnitines by the activity of carnitine palmitoyltrans-
ferase (CPT) 1, which is also localized in the outer mito-
chondrial membrane and catalyzes the formation of acyl-
carnitine from acyl-CoA and free carnitine. Acyl-carnitines
are transported across the inner mitochondrial membrane
by carnitine acylcarnitine translocase in exchange for free
carnitine. CPT2, which is expressed on the mitochondrial
inner membrane, converts acyl-carnitines back to acyl-
CoAs. Within the mitochondrial matrix, acyl-CoAs are
sequentially broken down by the b-oxidation cycle into
acetyl-CoAs. This process requires four enzymes: acyl-
CoA dehydrogenase, 2-enoyl-CoA hydratase, 3-hydroxya-
cyl-CoA dehydrogenase and 3-oxoacyl-CoA thiolase.
Acetyl-CoAs are further oxidized in the tricarboxylic acid
(TCA) cycle where NADH and FADH2 are generated for
ATP synthesis by the electron transport chain. When
present in excess, acetyl-CoAs are processed to ketone
bodies by a series of reactions for which 3-hydroxy-3-
methylglutaryl-CoA (HMG-CoA) synthase is the rate-
limiting enzyme [42].
In the postprandial state, b-oxidation in the liver is
suppressed. This occurs in part due to the antilipolytic
effect of insulin on white adipose tissue, which reduces the
ﬂux of non-esteriﬁed fatty acid to the liver, and in part due
to the direct control by glucose and insulin over the rate of
fatty acid entry into the mitochondria [43]. As described
above, insulin facilitates de novo lipogenesis through
upregulation and activation of SREBP1c and induction of
ACC. Malonyl-CoA produced by ACC activity inhibits the
activity of CPT1, and thereby decreases the rate of b-oxi-
dation by reducing fatty acid entry to mitochondria.
Cytosolic ACC1, the major isoform of ACC in liver,
contributes malonyl-CoA for fatty acid synthesis [44] and
for inhibition of fatty acid oxidation [45]. By contrast,
malonyl-CoA produced by ACC2, which is localized
in mitochondria, serves primarily to suppress fatty acid
J Gastroenterol (2013) 48:434–441 437
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regulation of malonyl-CoA as the molecular switch
between fatty acid synthesis and oxidation [47].
During the fasting state, glucagon promotes fatty acid
oxidation. Glucagon signaling activates AMP-activated
protein kinase (AMPK), which in turn inactivates ACC1
and ACC2 by phosphorylation [47]. This blocks the syn-
thesis of malonyl-CoA and is accompanied by activation
malonyl-CoA decarboxylase, which enhances destruction
of malonyl-CoA [47]. These combined effects decrease
fatty acid synthesis and activate ketogenesis. The hepatic
expression of peroxisome proliferator-activated receptor
(PPAR) a is also essential for glucagon-mediated fatty acid
oxidation [48]. PPARa is a fatty acid-activated nuclear
hormone receptor that plays a central role in the tran-
scriptional regulation of lipid and glucose metabolism [49].
Activated PPARa forms a heterodimer with RXR, which
binds to speciﬁc DNA sequences known as peroxisome
proliferator response elements (PPREs). This transcrip-
tional complex promotes the expression of genes that
mediate fatty acid oxidation. Although a common feature
of PPARa target genes, PPREs have not been identiﬁed in
all genes that are regulated by this transcription factor [49].
Recent studies have demonstrated that the circulating
hormone ﬁbroblast growth factor 21 (FGF21) is directly
induced by PPARa [50]. In mice, FGF21 promotes fatty
acid oxidation and ketogenesis, as well as gluconeogenesis
during fasting. FGF21 is primarily expressed in liver and
released to the circulation to function as an endocrine
hormone. In humans, the regulatory role of FGF21 in fatty
acid oxidation is less clear [51].
Accumulating evidence also indicates that members of
the sirtuin gene family, especially SIRT1 and SIRT3, play
important roles in fatty acid oxidation during conditions of
caloric deprivation [52]. Sirtuins control target proteins by
deacetylating histones and other transcriptional regulators.
In rodents, both SIRT1 and SIRT3 are increased in
response to fasting and activate proteins that promote fatty
acid oxidation. SIRT1 enhances fatty acid oxidation by
activating PPARa and its co-activator, peroxisome prolif-
erator-activated receptor-gamma coactivator 1 a (PGC1a).
SIRT1 also reduces lipogenesis by inhibiting SREBP1c.
SIRT3, which is localized to mitochondria, promotes
ß-oxidation by activating acyl-CoA dehydrogenase.
Studies in human NAFLD patients have yielded mixed
results with respect to alterations in rates of fatty acid
oxidation [38]. Impaired ATP production has been descri-
bed in patients with NAFLD and insulin resistance [53,
54]. Others have reported evidence for increased rates of
fatty acid oxidation in NAFLD [55, 56]. The latter ﬁndings
suggest that increased mitochondrial activity could pro-
mote oxidative stress within the liver and contribute to the
development of NASH [57].
VLDL secretion
The liver secretes triglycerides in the form of VLDL par-
ticles for delivery to peripheral tissues, including skeletal
muscle, cardiac muscle and adipose tissue. VLDL is a
triglyceride-rich lipoprotein, which contains a hydrophobic
core composed mainly of triglycerides and cholesteryl
esters. This core is surrounded by a hydrophilic coating,
which consists of a monolayer of phospholipids, as well as
unesteriﬁed cholesterol. These constituents are delivered to
peripheral tissues as VLDL is converted by lipoprotein
lipase to higher-density and smaller-sized atherogenic
particles, including low density lipoproteins (LDL) and
intermediate density lipoproteins (IDL). Each VLDL par-
ticle is stabilized by a single molecule of apolipoprotein B
100 (apoB 100). ApoB 100 is a long polypeptide that is
lipidated with triglycerides within the lumen of ER while it
is being translated and translocated across the ER mem-
brane. Lipidation of apoB 100 is facilitated by microsomal
triglyceride transfer protein (MTP), an ER resident protein
that has both apoB 100 binding and lipid transfer domains
[58]. Nascent VLDL particles, packaged into VLDL
transport vesicles, are transported from ER to Golgi
apparatus [59]. During these processes, the maturing
VLDL particles are further lipidated by the activity of MTP
[60]. Upon maturation, VLDL particles are exocytosed into
the plasma within the space of Disse.
The VLDL secretion rate appears to depend not only on
the availability of hepatic triglycerides, but also on the
overall capacity for VLDL assembly. When the triglyceride
availability is reduced, lipid-free apoB 100 is degraded by
both proteasomal and non-proteasomal pathways [61].
Insulin plays an important role in regulating the capacity
for VLDL assembly. In response to insulin action, apoB
100 is degraded by mechanisms that appear to include
autophagy [61]. Moreover, insulin negatively regulates the
expression of MTP, which is a target gene of FoxO1, the
same transcription factor responsible for induction of glu-
coneogenic genes [62]. Nuclear FoxO1 binds to MTP
promoter regions and increases transcription [62]. Phos-
phorylation of FoxO1 in response to insulin signaling
prevents its translocation from the cytosol to the nucleus.
Although insulin-mediated lipogenesis in the fed state
would appear to make more triglycerides be available for
VLDL assembly, the net effect of insulin is to limit the
postprandial secretion of VLDL. This allows the prefer-
entially delivery of dietary triglycerides to peripheral tis-
sues in the form of apoB 48-containing chylomicron
particles.
Impaired VLDL assembly and secretion result in
excessive lipid accumulation in liver. Hepatic steatosis has
been reported in subjects with hypobetalipoproteinemia
(i.e., mutations in apoB 100) [63] or abetalipoproteinemia
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been observed in liver-speciﬁc MTP knockout mice [65],
whereas mice with liver-speciﬁc overexpression of MTP
exhibit VLDL overproduction and elevated plasma tri-
glyceride levels [66]. Hepatic steatosis may also be induced
by drugs that inhibit MTP activity [67]. By contrast,
NAFLD is characterized by overproduction of VLDL
particles, which reﬂects enhanced de novo lipogenesis plus
lipolysis of intrahepatic and intra-abdominal fat [24]. In
these subjects, lipid availability for VLDL assembly is
increased, and this is combined with the failure of insulin
to suppress VLDL production. Due to the increased
availability of triglycerides, apoB 100 is not degraded, and
MTP expression is increased due to sustained nuclear
localization of FoxO1 [68]. Consequently, hypertriglycer-
idemia is a common ﬁnding in NAFLD patients. Although
chronic exposure to insulin drives VLDL overproduction
[68], augmented VLDL secretion does not compensate the
triglyceride overproduction in liver, so that steady state
hepatic triglyceride concentrations remain increased.
Moreover, apoB 100 secretion is not increased in NAFLD,
suggesting that apoB 100 production limits the liver’s
capacity to export hepatic triglycerides [24]. In this con-
nection, prolonged exposure of the liver to non-esteriﬁed
fatty acids, such as that occuring in the setting of insulin
resistance, promotes excessive ER stress, and this leads to
the degradation of apoB 100, thereby decreasing triglyc-
eride secretion and worsening steatosis [69].
Conclusions
Under physiological conditions, the delicate balance
between accumulation and disposal results in low steady
state triglyceride concentrations within the liver. In the
setting of overnutrition and insulin resistance, this balance
is altered by a multiplicity of events that increases hepatic
triglyceride concentrations and results in steatosis.
Although rare genetic defects in fatty acid oxidation- or
VLDL secretion-related genes may induce hepatic stea-
tosis in humans, more common human genetic variants
have now been linked to NAFLD susceptibility [1].
However, the roles of these genes in the pathogenesis of
hepatic steatosis are not well understood. The I148M
missense mutation in patatin-like phospholipase domain-
containing (PNPLA) 3 is most consistently associated
with NAFLD. Indicative of its complex regulatory role in
hepatic triglyceride metabolism, overexpression of
PNPLA3 in a transgenic mouse model promoted NAFLD
in the absence of insulin resistance by increasing the
formation of fatty acids and triglycerides, while impairing
triglyceride hydrolysis [70]. Additional studies on
PNPLA3 and other genes linked to NAFLD should
advance our understanding of the molecular pathogenesis
of this common disorder.
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